SCHEMBL7174754

SCHEMBL7174754

Cc1cccc(Cl)c1C(=O)P(=O)(C(=O)c1c(Cl)cc(Cl)cc1Cl)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 1/20 0.40
FABP4 P15090 1/20 0.40
TYK2 P29597 1/20 0.40
ITGB1 P05556 3/20 0.37
ITGA4 P13612 3/20 0.37
ITGA2 P17301 1/20 0.37
ITGB7 P26010 1/20 0.37
ABL1 P00519 1/20 0.37
SRC P12931 1/20 0.37
TRPM4 Q8TD43 1/20 0.37
MAPT P10636 3/20 0.36
GAA P10253 2/20 0.36
UTS2R Q9UKP6 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PTPRC P08575 1/20 0.35
KMT2A Q03164 1/20 0.35
ITGB2 P05107 1/20 0.35
ICAM1 P05362 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174651 0.94 FABP3 (0.39) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7179862 0.93 TYK2 (0.44) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7183633 0.92 ALDH1A1 (0.40) FABP3FABP4TYK2MAPTGAA
SCHEMBL7182453 0.90 TYK2 (0.44) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7174811 0.90 TYK2 (0.44) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7182411 0.86 KMT2A (0.40) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7183686 0.86 TYK2 (0.40) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7180494 0.86 TYK2 (0.40) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7182628 0.86 TYK2 (0.42) FABP3FABP4TYK2ITGB1ITGA4
SCHEMBL7183064 0.86 TYK2 (0.42) FABP3FABP4TYK2ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 FABP3 3252/4885FABP4 4550/4885TYK2 1285/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 FABP3 2807/4885FABP4 4256/4885TYK2 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.